MedTrace Logo

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

NCT03706547 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-10-16

No results posted yet for this study

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory multiple myeloma.

Conditions

  • Multiple Myeloma in Relapse
  • Multiple Myeloma Progression

Interventions

BIOLOGICAL

anti-CD19/BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

Sponsors & Collaborators

  • Hrain Biotechnology

    collaborator UNKNOWN

  • Shanghai East Hospital

    collaborator OTHER

  • Peng Liu

    lead OTHER

Principal Investigators

  • Peng Liu, M.D. & Ph.D. · Shanghai Zhongshan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2020-07-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706547 on ClinicalTrials.gov